Physician profile
Michael Israel
NPI 1184907362
$375,082.35
in general payments reported to CMS, 2019-2025
44 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $33K · 2021: $63K · 2022: $79K · 2023: $79K · 2024: $51K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $159K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,600 · Food and Beverage: $3,740 · Travel and Lodging: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $158,789.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,600.00 |
| Food and Beverage | $3,740.49 |
| Travel and Lodging | $491.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $350,195.99 | 2019-2025 | |
| Amgen INC. | $17,824.95 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $1,985.03 | 2019-2025 | |
| Novo Nordisk INC | $787.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $670.62 | 2021-2024 | |
| Allergan, INC. | $367.31 | 2019-2021 | |
| Astellas Pharma US INC | $356.20 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $350.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $339.94 | 2019-2025 | Rexulti |
| Pfizer INC. | $275.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $148.32 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.06 | 2019-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $138.51 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.26 | 2021-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.07 | 2024-2025 | Caplyta |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $121.56 | 2019-2024 | Gardasil, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $113.51 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Axsome Therapeutics, INC. | $102.06 | 2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company Ltd. | $97.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $89.51 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $80.01 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.78 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $50.24 | 2022-2025 | Nexletol |
| Lilly USA, LLC | $44.93 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $44.13 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $41.53 | 2025 | Symplicity G3 |
| Eisai INC. | $41.52 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $33.88 | 2023-2024 | Edarbi, Horizant |
| Sunovion Pharmaceuticals INC. | $31.56 | 2019 | |
| Amarin Pharma, INC. | $30.50 | 2020 | |
| Alkermes, INC. | $29.01 | 2023 | Vivitrol |
| Idorsia Pharmaceuticals US INC | $27.30 | 2023 | Quviviq |
| Organon LLC | $22.94 | 2023 | Nexplanon |
| Ultragenyx Pharmaceutical INC. | $19.94 | 2023 | |
| Sanofi Pasteur INC. | $18.78 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.60 | 2019 | |
| Exeltis, USA INC. | $16.04 | 2021 | |
| Biodelivery Sciences International, INC. | $15.15 | 2019 | |
| Seqirus USA INC | $15.05 | 2025 | Flucelvax, Fluad |
| Lundbeck LLC | $14.36 | 2025 | Rexulti |
| Abbott Laboratories | $14.09 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.45 | 2021 | |
| Collegium Pharmaceutical, INC. | $12.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $2.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Israel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.